Navigation Links
TGen Physician-In-Chief Dr. Daniel D. Von Hoff wins ASCO award
Date:4/1/2010

PHOENIX, Ariz. April 1, 2010 Dr. Daniel D. Von Hoff, Physician-in-Chief for the Translational Genomics Research Institute (TGen), has won a top award from the American Society of Clinical Oncology (ASCO) for his cancer research.

Dr. Von Hoff, M.D., F.A.C.P., will receive the 2010 David A. Karnofsky Memorial Award and Lecture at ASCO's 46th Annual Meeting, June 4-8 at the McCormick Place in Chicago.

ASCO will present the award to Dr. Von Hoff "for his outstanding achievements in cancer research and for his impact on the treatment of patients with cancer."

Dr. Von Hoff is an internationally recognized physician-scientist who has contributed to the development of numerous anticancer agents, including paclitaxel, docetaxel, irinotecan and gemcitabine. He also is the Chief Scientific Officer of TGen Clinical Research Services at Scottsdale Healthcare and at US Oncology, and is a Clinical Professor of Medicine at the University of Arizona College of Medicine.

Each year through its Special Awards Program, ASCO recognizes quality researchers, patient advocates and leaders of the global oncology community who through their work have made significant contributions to enhancing cancer care. These recipients of ASCO's highest, most prestigious awards collectively represent significant strides in cancer treatment and leadership in the oncology community.

"The work of this year's awardees collectively represents decades of commitment to improving the care and quality of life for people living with cancer," said Richard L. Schilsky, M.D., ASCO's Immediate Past President and Chair of the Special Awards Selection Committee. "Our understanding of the biological basis of cancer and our ability to transform that knowledge into better treatments for patients have been enhanced by their contributions and it is an honor to present them ASCO's highest awards."

The David A. Karnofsky Memorial Award was first presented in 1970. It recognizes outstanding contributions to cancer research, diagnosis and/or treatment. A lecture is given during the opening session of the ASCO Annual Meeting.

The award is named after David A. Karnofsky, 1914-1969, an American clinical oncologist and specialist in cancer chemotherapy who was affiliated with the Memorial Sloan-Kettering Cancer Center. He is known for developing the Karnofsky scale, an index for determining a patient's suitability for therapy and for estimating a patient's physical state, performance and prognosis after a therapeutic procedure.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Daniel Simon, MD Urges People with Diabetes to Protect Sight by Getting Diabetic Eye Exam
2. Dr. Daniel Von Hoff named honoree of Scottsdale Healthcare Foundation Honor Ball
3. Statement by Dr. Daniel Carucci, Vice President for Global Health for the United Nations Foundation, on Progress Shown in World Malaria Report 2009
4. Daniel Jordan Fiddle Foundation for Adults with Autism Offers Free Epilepsy First-Aid Brochure
5. Veteran Journalist Daniel Weintraub Launches HealthyCal.org
6. Pennsylvania EPA Awards Abington Memorial Hospital Funding for Green Projects
7. Carol Milgard Breast Center Awarded Highest Government Rating for Mammography Sites
8. Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinsons Disease Biomarker Pipeline
9. New Orleans Saints Offensive Line Honored with First Madden Most Valuable Protectors Award Presented by Prilosec OTC(R)
10. Frost & Sullivan Ghanaian Pharmaceutical Industry Innovation & Advancement Award Conferred on LaGray Chemical Company
11. UNFPA Honoured With Human Rights Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose Combination Drug ... p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose combination products ... increased attention from all stakeholders in the development of new chemical entities. , ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Leadership Series at Zuckerberg San Francisco General Hospital on April 5-7. The series ... behaviors and create new habits. The workshops cover a broad range of topics, ...
(Date:2/12/2016)... , ... February 12, 2016 , ... The Jones Agency, ... communities across eastern Texas, is launching a cooperative charity drive with the Tarrant Area ... Serving more than 50,000 individuals and families in need, the Tarrant County Food Bank ...
(Date:2/12/2016)... ... ... Miami Dental Specialists is excited to bring patients the choice of ceramic, ... Dental Specialists will offer the non-metal implants as a safe, holistic and hygienic approach ... the dental implant manufacturer, Straumann, to bring this cutting-edge technology to Miami. ...
(Date:2/12/2016)... ... 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased ... upcoming Feb. 24 webinar that will discuss ways health plans and PBMs are ... the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors to treat cholesterol. ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Calif. , Feb. 12, 2016  SI-BONE, Inc., a medical ... ® ("iFuse"), a minimally invasive surgical (MIS) device indicated for ... National Government Services, Inc. (NGS), the Medicare Administrative Contractor (MAC) covering ... , Maine , Massachusetts ... , New York , Rhode Island ...
(Date:2/12/2016)... Calif. , Feb. 12, 2016  Sequent Medical, ... in a study to evaluate the safety and effectiveness ... the treatment of ruptured intracranial aneurysms.  Prof Laurent ... Hospital, in Paris, France and ... patient. France and Germany.  ...
(Date:2/12/2016)... Lilly and Company (NYSE: LLY ) today announced that ... regimen patent would not presently be infringed by Actavis marketing ... Italy and Spain ... solution.  --> --> ... that Lilly,s patent would be indirectly infringed by Actavis marketing ...
Breaking Medicine Technology: